About the Company
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ATRA News
Atara Biotherapeutics Inc’s (ATRA) 9.36% Gain Is A Reason To Reconsider.
ATRA’s current price about -0.96% and 7.83% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 50.64, while 7-day volatility ratio is ...
ATRA Apr 2024 0.500 call
THOUSAND OAKS, Calif., February 29, 2024--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...
Atara Biotherapeutics Inc earnings beat by $0.07, revenue topped estimates
Investing.com - Atara Biotherapeutics Inc (NASDAQ: ATRA) reported fourth quarter EPS of $-0.38, $0.07 better than the analyst estimate of $-0.45. Revenue for the quarter came in at $2.84M versus ...
Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
February 29, 2024--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging ...
Atara Biotherapeutics Inc ATRA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Atara Biotherapeutics Inc earnings beat by $0.07, revenue topped estimates
Investing.com - Atara Biotherapeutics Inc (NASDAQ: ATRA) reported fourth quarter EPS of $-0.38, $0.07 better than the analyst estimate of $-0.45. Revenue for the quarter came in at $2.84M versus the ...
Atara Biotherapeutics Inc ATRA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Atara Biotherapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
ATRA Atara Biotherapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Atara Biotherapeutics Inc (ATRA)
ATRA option chain data. View the call and put strike options, last price, change, volume and implied volatility for Atara Biotherapeutics Inc. Quotes and Analysis tables are both available to toggle ...
Loading the latest forecasts...